



CLAIMS

It is claimed:

1. A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein A is A1 or A2,



and wherein

each R¹ is independently halogen, -CN, -C₁₋₃alkyl, or -OC₁₋₃alkyl, wherein the alkyl of C₁₋₃alkyl and OC₁₋₃alkyl is substituted with 0 to 3 F atoms;

m is 0, 1, 2, or 3;

X-L is N-CH₂, CHCH₂, or cyclopropyl;

Y is CH or N;

Z^{A1} is CH, CR², or N;

Z^{A2} is CH, CR², or N;

Z^{A3} is CH, CR², or N, provided that Z^{A2} and Z^{A3} are not simultaneously N; and further provided that one of Z^{A2} and Z^{A3} is N when X-L is N-CH₂;

each R² is independently F, Cl, or -CN;

each R³ is independently F, -OH, -CN, -C₁₋₃alkyl, -OC₁₋₃alkyl, or -C₃₋₄cycloalkyl, or 2 R³s may together cyclize to form -C₃₋₄spirocycloalkyl, wherein the alkyl of C₁₋₃alkyl and OC₁₋₃alkyl, cycloalkyl, or spirocycloalkyl may be substituted as valency allows with 0 to 3 F atoms and with 0 to 1 -OH;

q is 0, 1, or 2;

R^4 is $-C_{1-3}\text{alkyl}$, $-C_{0-3}\text{alkylene}-C_{3-6}\text{cycloalkyl}$, $-C_{0-3}\text{alkylene}-R^5$, or $-C_{1-3}\text{alkylene}-R^6$, wherein said alkyl may be substituted as valency allows with 0 to 3 substituents independently selected from 0 to 3 F atoms and 0 to 1 substituent selected from $-C_{0-1}\text{alkylene}-\text{CN}$, $-C_{0-1}\text{alkylene}-\text{OR}^O$, and $-\text{N}(\text{R}^N)_2$, and

5 wherein said alkylene and cycloalkyl may be independently substituted as valency allows with 0 to 2 substituents independently selected from 0 to 2 F atoms and 0 to 1 substituent selected from $-C_{0-1}\text{alkylene}-\text{CN}$, $-C_{0-1}\text{alkylene}-\text{OR}^O$, and $-\text{N}(\text{R}^N)_2$;

R^5 is a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:

10 0 to 1 oxo ($=\text{O}$),
 0 to 1 $-\text{CN}$,
 0 to 2 F atoms, and
 0 to 2 substituents independently selected from $-C_{1-3}\text{alkyl}$ and $-\text{OC}_{1-3}\text{alkyl}$, wherein the alkyl of $C_{1-3}\text{alkyl}$ and $\text{OC}_{1-3}\text{alkyl}$ may be substituted with 0 to 3 substituents as valency
 15 allows independently selected from:
 0 to 3 F atoms,
 0 to 1 $-\text{CN}$, and
 0 to 1 $-\text{OR}^O$;

R^6 is a 5- to 6-membered heteroaryl, wherein said heteroaryl may be substituted with 0
 20 to 2 substituents as valency allows independently selected from:


0 to 2 halogens,
 0 to 1 substituent selected from $-\text{OR}^O$ and $-\text{N}(\text{R}^N)_2$, and
 0 to 2 $-C_{1-3}\text{alkyl}$, wherein the alkyl may be substituted with 0 to 3 substituents as valency
 allows independently selected from:
 25 0 to 3 F atoms, and
 0 to 1 $-\text{OR}^O$;

each R^O is independently H, or $-C_{1-3}\text{alkyl}$, wherein $C_{1-3}\text{alkyl}$ may be substituted with 0 to
 3 F atoms;


each R^N is independently H, or $-C_{1-3}\text{alkyl}$;

30 Z^1 , Z^2 , and Z^3 are each $-\text{CR}^Z$, or
 one of Z^1 , Z^2 , and Z^3 is N and the other two are $-\text{CR}^Z$; and
 each R^Z is independently H, F, Cl, or $-\text{CH}_3$.

2. The compound of claim 1, wherein the compound is a compound of Formula II




or a pharmaceutically acceptable salt thereof, wherein A is A1 or A2,




and wherein

each R^1 is independently F, Cl, or $-CN$; and
m is 0, 1, or 2.

3. The compound of claim 1, wherein the compound is a compound of Formula III



or a pharmaceutically acceptable salt thereof, wherein A is A1 or A2,




and wherein

each R^1 is independently F, Cl, or $-CN$; and

m is 0, 1, or 2.

4. The compound of any one of claims 1 to 3, wherein A is A1, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4, wherein the compound is a compound of Formula IV



IV

or a pharmaceutically acceptable salt thereof, wherein

each R¹ is independently F, Cl, or -CN;

m is 0, or 1;

q is 0 or 1; and

R³ is -CH₃.

6. The compound of claim 5, wherein Zᴬ¹ is CH, or CR²; R² is F; or a pharmaceutically acceptable salt thereof.

7. The compound of claim 5, wherein Zᴬ¹ is N, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 or claim 2, wherein A is A2, q is 0 or 1; and


R³ is -CH₃;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8, wherein Zᴬ² is CH, or CR²; and Zᴬ³ is N; or a pharmaceutically acceptable salt thereof.

10. The compound of claim 8, wherein Zᴬ² is N and Zᴬ³ is CH, or CR², or a pharmaceutically acceptable salt thereof.

11. The compound of any one of claims 1, 9, or 10, wherein the compound is a compound of Formula V



V

or a pharmaceutically acceptable salt thereof, wherein

each R^1 is independently F, Cl, or $-\text{CN}$;

5 m is 0, or 1;


Z^{A2} is CH, CR^2 , or N;

Z^{A3} is CH, CR^2 , or N, provided that Z^{A2} and Z^{A3} are not simultaneously N; and

each R^2 is F.

12. The compound of any one of claims 1, 9, or 10, wherein the compound is a compound of

10 Formula VI



VI

or a pharmaceutically acceptable salt thereof, wherein

each R^1 is independently F, Cl, or $-\text{CN}$;

15 m is 0, or 1;

R^3 is $-\text{CH}_3$;

q is 0, 1, or 2;

Z^{A2} is CH, CR^2 , or N;

Z^{A3} is CH, CR^2 , or N, Z^{A2} and Z^{A3} are not simultaneously N; and further provided that one

20 of Z^{A2} and Z^{A3} is N when X-L is N- CH_2 ;

R^2 is F; and

Y is CH or N.

13. The compound of any one of claims 1 to 12, wherein R_4 is $-\text{CH}_2-\text{R}^5$, wherein R^5 is the 4- to 5-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 2 F atoms, and

0 to 1 substituent selected from oxo ($=\text{O}$), $-\text{OCH}_3$ and $-\text{CH}_2\text{OCH}_3$;
or a pharmaceutically acceptable salt thereof.

14. The compound of any one of claims 1 to 12, wherein R_4 is $-\text{CH}_2-\text{R}^6$, wherein R^6 is the 5-membered heteroaryl, wherein said heteroaryl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 2 halogens, wherein the halogen is independently selected from F and Cl,

0 to 1 $-\text{OCH}_3$, and

0 to 1 $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CF}_3$, or $-\text{CH}_2\text{CH}_2\text{OCH}_3$;

or a pharmaceutically acceptable salt thereof.

15. The compound of any one of claims 1 to 12, wherein R_4 is $-\text{C}_{1-3}\text{alkyl}$, wherein said alkyl may be substituted as valency allows with 0 to 3 substituents independently selected from 0 to 3 F atoms and 0 to 1 substituent that is $-\text{C}_{0-1}\text{alkylene}-\text{OR}^0$.

16. A compound that is

2-[(4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-[(4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid;

2-[(4-{2-[(4-cyano-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid;

2-[(4-{2-[(4-cyano-2-fluorobenzyl)oxy]pyridin-3-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-[(4-{3-[(4-chloro-2-fluorobenzyl)oxy]pyrazin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

or a pharmaceutically acceptable salt thereof.

17. A compound that is

2-(6-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-(6-{2-[(4-chloro-2-fluorobenzyl)oxy]-5-fluoropyrimidin-4-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-(6-{2-[(4-chloro-2-fluorobenzyl)oxy]-5-fluoropyrimidin-4-yl}-6-azaspiro[2.5]oct-1-yl)-1-(1,3-oxazol-2-ylmethyl)-1H-benzimidazole-6-carboxylic acid;

2-(6-{6-[(4-cyano-2-fluorobenzyl)oxy]-5-fluoropyridin-2-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-(6-{6-[(4-cyano-2-fluorobenzyl)oxy]-3-fluoropyridin-2-yl}-6-azaspiro[2.5]oct-1-yl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

5 or a pharmaceutically acceptable salt thereof.

18. A compound that is

2-[(4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyrimidin-4-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-[[[(2S)-4-{2-[(4-chloro-2-fluorobenzyl)oxy]-5-fluoropyrimidin-4-yl}-2-methylpiperazin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-[[[(2S)-4-{2-[(4-chloro-2-fluorobenzyl)oxy]pyrimidin-4-yl}-2-methylpiperazin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the compound of any one of claims 1 to 18, or
15 a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

20. — ~~A method of treating cardiometabolic and associated diseases comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein the disease is T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease, schizophrenia, impaired cognition,~~

~~inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, prevention or treatment of Polycystic Ovary Syndrome and treatment of addiction.~~

20. Use of the compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19, in the manufacture of a medicament for

5 treating cardiometabolic and associated diseases, wherein the disease is T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders,

10 weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension,

15 restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism,

20 conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, prevention or treatment of Polycystic Ovary Syndrome and treatment of addiction.